GT200100151A - Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b. - Google Patents

Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b.

Info

Publication number
GT200100151A
GT200100151A GT200100151A GT200100151A GT200100151A GT 200100151 A GT200100151 A GT 200100151A GT 200100151 A GT200100151 A GT 200100151A GT 200100151 A GT200100151 A GT 200100151A GT 200100151 A GT200100151 A GT 200100151A
Authority
GT
Guatemala
Prior art keywords
glucogeno
sintasa
inhibitors
derivatives
indolil
Prior art date
Application number
GT200100151A
Other languages
English (en)
Inventor
Leyi Gong
Andrew Grupe
Gary Allen Peltz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100151A publication Critical patent/GT200100151A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LOS DERIVADOS DE LA 3INDOLIL4FENIL1HPIRROL2,5DIONA DE FORMULA (I) DONDE R1A R6 SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON UTILES COMO INHIBIDORES DE LA GLUCOGENO SINTASA QUINASA3B Y, POR TANTO, PUEDEN SER UTILIZADOS PARA EL TRATAMIENTO DE LAS ENFERMEDADES MEDIADAS POR LA GSK3BETA, TALES COMO LA ENFERMEDAD DE ALZHEIMER, OBESIDAD, DIABETES, ENFERMEDAD CARDIOVASCULAR, ARTERIOSCLEROTICA, SINDROME OVARICO POLIQUISTICO, SINDROME X, ETC.
GT200100151A 2000-07-27 2001-07-26 Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b. GT200100151A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22105800P 2000-07-27 2000-07-27

Publications (1)

Publication Number Publication Date
GT200100151A true GT200100151A (es) 2002-05-23

Family

ID=22826151

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100151A GT200100151A (es) 2000-07-27 2001-07-26 Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b.

Country Status (32)

Country Link
US (2) US6479490B2 (es)
EP (1) EP1307447B1 (es)
JP (1) JP3984157B2 (es)
KR (1) KR20030017655A (es)
CN (1) CN1185229C (es)
AR (1) AR033989A1 (es)
AT (1) ATE284885T1 (es)
AU (1) AU2001293702A1 (es)
BR (1) BR0112965A (es)
CA (1) CA2417277A1 (es)
CZ (1) CZ2003555A3 (es)
DE (1) DE60107857T2 (es)
EC (1) ECSP034452A (es)
ES (1) ES2233691T3 (es)
GT (1) GT200100151A (es)
HK (1) HK1058670A1 (es)
HR (1) HRP20030030A2 (es)
HU (1) HUP0301431A2 (es)
IL (1) IL153851A0 (es)
JO (1) JO2293B1 (es)
MA (1) MA26936A1 (es)
MX (1) MXPA03000695A (es)
NO (1) NO20030328D0 (es)
NZ (1) NZ523462A (es)
PA (1) PA8523001A1 (es)
PE (1) PE20020338A1 (es)
PL (1) PL366701A1 (es)
RU (1) RU2003104796A (es)
UY (1) UY26857A1 (es)
WO (1) WO2002010158A2 (es)
YU (1) YU4403A (es)
ZA (1) ZA200300216B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6593600A (en) * 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
WO2002029091A2 (en) * 2000-10-02 2002-04-11 Reddy Us Therapeutics, Inc. Methods and compositions for the treatment of inflammatory diseases
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
IL155618A0 (en) * 2000-11-07 2003-11-23 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
EP1432679A1 (en) * 2001-09-24 2004-06-30 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
JP4237066B2 (ja) * 2002-01-10 2009-03-11 エフ．ホフマン−ラ ロシュ アーゲー 骨形成を増加させるための薬物の製造におけるＧＳＫ−３β阻害剤の使用
JP4414232B2 (ja) 2002-03-05 2010-02-10 イーライ リリー アンド カンパニー キナーゼ阻害物質
ES2289274T3 (es) * 2002-03-08 2008-02-01 Eli Lilly And Company Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3.
SE0200979D0 (sv) * 2002-03-28 2002-03-28 Astrazeneca Ab New compounds
SE0302546D0 (sv) 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
PE20040079A1 (es) * 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
RU2004135382A (ru) 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы
EP1513520B1 (en) 2002-06-05 2008-09-24 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
GB0303319D0 (en) 2003-02-13 2003-03-19 Novartis Ag Organic compounds
US7250444B2 (en) * 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
US7109436B2 (en) * 2003-08-29 2006-09-19 General Electric Company Laser shock peening target
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
US20070142401A1 (en) * 2003-10-27 2007-06-21 Novartis Ag Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
WO2005107465A1 (en) * 2004-05-12 2005-11-17 Bayer Cropscience Gmbh Plant growth regulation
EP1819697B1 (en) 2004-12-08 2012-08-01 Johannes Gutenberg-Universität Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
JP4747364B2 (ja) * 2005-04-04 2011-08-17 独立行政法人産業技術総合研究所 紫外線皮膚炎抑止剤およびアトピー性皮膚炎抑止剤
EP1885454A2 (en) 2005-05-04 2008-02-13 DeveloGen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
ES2446269T3 (es) 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
WO2008080824A1 (en) * 2006-12-29 2008-07-10 F. Hoffmann-La Roche Ag Aromatic sulfonated ketals
JP5658664B2 (ja) * 2008-06-25 2015-01-28 フォルム ファーマシューティカルズ、インコーポレイテッド １，２−二置換複素環式化合物
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TWI526421B (zh) * 2010-09-08 2016-03-21 住友化學股份有限公司 製造嗒酮化合物的方法及其中間物
EP2474541A1 (en) 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
KR20130034672A (ko) * 2011-09-28 2013-04-08 김동식 보텍스타입 열교환기
KR101440724B1 (ko) * 2013-03-29 2014-09-18 중앙대학교 산학협력단 글리코겐 신타아제 키나아제-3베타 억제물질을 유효성분으로 포함하는 난소과립세포종양의 예방 또는 치료용 약학적 조성물 및 건강기능성식품 조성물
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2018132636A1 (en) * 2017-01-12 2018-07-19 The Research Foundation For The State University Of New York [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method
CN112538458A (zh) 2020-11-26 2021-03-23 北京赛尔湃腾科技咨询合伙企业(有限合伙) 用于重编程细胞的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
GB9123396D0 (en) 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
CA2116460A1 (en) 1993-03-02 1994-09-03 Mitsubishi Chemical Corporation Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being
AU678435B2 (en) 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
JP2000502097A (ja) 1995-12-20 2000-02-22 メディカル、リサーチ、カウンシル タンパク質合成の制御、および作用薬のスクリーニング法
WO1997041854A1 (en) 1996-05-07 1997-11-13 The Trustees Of The University Of Pennsylvania Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
SE9603285D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
GB9828640D0 (en) * 1998-12-23 1999-02-17 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
BR0112965A (pt) 2003-07-08
EP1307447B1 (en) 2004-12-15
CN1185229C (zh) 2005-01-19
DE60107857D1 (de) 2005-01-20
US6479490B2 (en) 2002-11-12
ZA200300216B (en) 2004-04-08
HUP0301431A2 (hu) 2003-08-28
PE20020338A1 (es) 2002-04-23
ATE284885T1 (de) 2005-01-15
CZ2003555A3 (en) 2004-03-17
ECSP034452A (es) 2003-03-10
JP3984157B2 (ja) 2007-10-03
JO2293B1 (en) 2005-09-12
HK1058670A1 (en) 2004-05-28
PL366701A1 (en) 2005-02-07
JP2004505078A (ja) 2004-02-19
US20020188018A1 (en) 2002-12-12
MA26936A1 (fr) 2004-12-20
AR033989A1 (es) 2004-01-21
YU4403A (sh) 2006-05-25
WO2002010158A3 (en) 2002-05-16
DE60107857T2 (de) 2005-12-08
CN1444581A (zh) 2003-09-24
NO20030328L (no) 2003-01-22
MXPA03000695A (es) 2003-06-04
PA8523001A1 (es) 2002-10-24
KR20030017655A (ko) 2003-03-03
CA2417277A1 (en) 2002-02-07
AU2001293702A1 (en) 2002-02-13
ES2233691T3 (es) 2005-06-16
WO2002010158A2 (en) 2002-02-07
US20020052397A1 (en) 2002-05-02
NZ523462A (en) 2004-09-24
RU2003104796A (ru) 2004-08-20
NO20030328D0 (no) 2003-01-22
EP1307447A2 (en) 2003-05-07
HRP20030030A2 (en) 2005-02-28
UY26857A1 (es) 2002-01-31
IL153851A0 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
GT200100151A (es) Derivados de 3-indolil-4-fenil-1h-pirrol-2,5-dione como inhibidores de glucogeno sintasa quinasa-3b.
PA8544901A1 (es) Derivados de oxazol
CR8147A (es) Derivados de pirido 2, 1a-isoquinolina, como inhibidores de dpp-iv
GT200100183A (es) Derivados de quinolina y quinazolina.
UY29636A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY29149A1 (es) Tiazolil-dihidro-indazoles
GT200600429A (es) Compuestos organicos
ATE440087T1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
AR047529A1 (es) Compuestos de quinolina sustituidos
PA8568401A1 (es) Inhibidores pirimidina y piridina biciclicos de la p38 quinasa
PA8632701A1 (es) Compuestos terapeuticos
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
UY28150A1 (es) Agentes terapeuticos
ECSP077360A (es) Compuestos sulfonamida
AR027355A1 (es) Acidos tiazolidincarboxilicos
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
ECSP056193A (es) Derivados sustituidos del pirrol
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
BRPI0519267A2 (pt) derivado de quinolina, seu uso, produÇço e medicamento contendo o mesmo
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
PA8581201A1 (es) Nuevos derivados de tiazol